Evidence map›Paper›PMID 41503706›Full record

SynthesisHypertension (Dallas, Tex. : 1979)2026

End Point-Based Threshold for the Ambulatory Arterial Stiffness Index.

Yi-Bang Cheng, De-Wei An, Dong-Yan Zhang, Yu-Ling Yu, Jesus D Melgarejo, José Boggia, Dries S Martens, Tine W Hansen, Kei Asayama, Takayoshi Ohkubo and 22 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Yi-Bang ChengDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0002-3822-3504
De-Wei AnDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.
Dong-Yan ZhangDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0003-0551-971X
Yu-Ling YuNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (D.-Y.Z., Y.-L.Y, T.W.H., K.A., K.S.-S., G.E.M., J.A.S).ORCID 0000-0002-8255-3770
Jesus D MelgarejoInstitute of Neuroscience, Neuro and Behavioral Health Integrated Service Unit, University of Texas Rio Grande Valley, Harlingen (J.D.M., G.E.M).ORCID 0000-0002-1382-1153
José BoggiaCentro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.).ORCID 0000-0002-1564-8534
Dries S MartensCenter for Environmental Sciences, Hasselt University, Diepenbeek, Belgium (D.S.M., T.S.N.).
Tine W HansenNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (D.-Y.Z., Y.-L.Y, T.W.H., K.A., K.S.-S., G.E.M., J.A.S).ORCID 0000-0003-2274-0352
Kei AsayamaNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (D.-Y.Z., Y.-L.Y, T.W.H., K.A., K.S.-S., G.E.M., J.A.S).ORCID 0000-0003-3365-0547
Takayoshi OhkuboDepartment of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A., T.O., M.K.).ORCID 0000-0002-3283-8196
Katarzyna Stolarz-SkrzypekNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (D.-Y.Z., Y.-L.Y, T.W.H., K.A., K.S.-S., G.E.M., J.A.S).
Qi-Fang HuangDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0002-9780-4237
Sofia MalyutinaInstitute of Internal and Preventive Medicine-Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk (S.M.).
Edoardo CasigliaDepartment of Medicine, University of Padua, Italy (E.C.).ORCID 0000-0002-0003-3289
Lars LindSection of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Sweden (L.L.).ORCID 0000-0003-2335-8542
Gladys E MaestreNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (D.-Y.Z., Y.-L.Y, T.W.H., K.A., K.S.-S., G.E.M., J.A.S).ORCID 0000-0001-5690-8833
Ji-Guang WangDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0001-8511-1524
Masahiro KikuyaDepartment of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A., T.O., M.K.).ORCID 0000-0002-3080-6107
Kalina Kawecka-JaszczThe First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland (K.S.-S., K.K.-J., M.R., J.A.S).
Eamon DolanSchool of Medicine, Stroke Service, University College Cork, Ireland (E.D.).
Edgardo SandoyaAsociación Española, Montevideo, Uruguay (E.S.).ORCID 0000-0003-4125-3293
Marek RajzerThe First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland (K.S.-S., K.K.-J., M.R., J.A.S).ORCID 0000-0001-7074-7263
Tim S NawrotResearch Unit Environment and Health, KU Leuven Department of Public Health and Primary Care (D.-Y.Z., Y.-L.Y., T.S.N.), University of Leuven, Belgium.ORCID 0000-0002-3583-3593
Krzysztof NarkiewiczHypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Poland (K.N.).ORCID 0000-0001-5949-5018
Wen-Yi YangDepartment of Cardiology, Shanghai General Hospital (W.-Y.Y.), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0003-1279-0866
Peter VerhammeCenter for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences (P.V.), University of Leuven, Belgium.ORCID 0000-0001-8698-2858
Jan FilipovskýDepartment of Internal Medicine II, University Hospital, Charles University Medical School, Pilsen, Czech Republic (J.F.).ORCID 0000-0002-1535-1263
Auxiliadora GracianiDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain (A.G., J.R.B).ORCID 0000-0002-6211-587X
José R BanegasDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain (A.G., J.R.B).ORCID 0000-0001-6152-9862
Yan Li *Department of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0002-5825-5968
Jan A Staessen *Department of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital (Y.-B.C, D.-W.A., D.-Y.Z., Q.-F.H., J.G.W., Y.L., J.A.S), Shanghai Jiao Tong University School of Medicine, China.ORCID 0000-0002-3026-1637
International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators

Funding

South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0M
Rio Grande Valley Alzheimer's Resource Center for Minority Aging Research: Partnerships for ProgressP30AG059305 · NIA · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Gladys E. Maestre · 2018 to 2026
$5.8M
NIA NIH HHS P30 AG059305NIA NIH HHS P30 AG066546
6 · The paper itself

Abstract

backgroundThe ambulatory arterial stiffness index (AASI) is increasingly used in clinical research and practice. This individual-participant meta-analysis aims to consolidate the prognostic accuracy of AASI in the general population and to derive an end point-based AASI risk threshold.

methodsIn 12 558 individuals enrolled in 14 population studies (48.8% women; mean age, 59.3 years), AASI was derived by regressing 24-hour diastolic on systolic blood pressure (mm Hg/mm Hg). Using Cox regression, the risk-carrying AASI threshold was established by examining stepwise increasing AASI levels and by determining the AASI level, yielding a 10-year risk similar to an office systolic pressure of 140 mm Hg.

resultsOver 10.7 years (median), 3027 all-cause deaths and 2183 cardiovascular end points occurred. In all participants, multivariable-adjusted hazard ratios expressing the all-cause deaths and cardiovascular end point risk per 1-SD AASI increment were 1.08 (95% CI, 1.04-1.13) and 1.13 (95% CI, 1.07-1.18). In a randomly defined subset of 8189 individuals, the risk-carrying AASI thresholds converged to 0.50 with hazard ratios (≥0.50 versus <0.50) of 1.14 (95% CI, 1.04-1.26) for all-cause deaths and 1.13 (95% CI, 1.01-1.26) for cardiovascular end point. In the replication sample (n=4369), these hazard ratios were 1.13 (95% CI, 1.01-1.26) and 1.19 (95% CI, 1.04-1.35). AASI continuous or per threshold significantly improved model performance. Analyses of secondary end points and subgroups stratified by sex, age, hypertension status and treatment, history of cardiovascular disease, and nocturnal dipping were confirmatory.

conclusionsOver and beyond traditional risk factors, AASI improves risk stratification. Exceeding the risk-carrying 0.50 AASI threshold necessitates increased vigilance in managing risk factors before irreversible cardiovascular complications occur.

Indexed as

Blood PressureBlood Pressure Monitoring, AmbulatoryCardiovascular DiseasesHypertensionVascular StiffnessAgedFemaleHumansMaleMiddle AgedPrognosisRisk AssessmentRisk Factorsarterial stiffnessblood pressurecardiovascular diseasesmorbiditymortality

Identifiers

PMID41503706
PMCPMC12928787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.